Panmira Pharmaceuticals, LLC

Amira Pharmaceuticals, Inc.

Brickell Biotech, Inc.

Jill Melissa Scott

Brian Andrew Stearns

John Howard Hutchinson

Nicholas Simon Stock

Jeannie M Arruda

Deborah Volkots

Thomas Jon Seiders

Yen Truong

Bowei Wang

Lucy Xiumin Zhao

Heather Renee Coate

Jeffrey Roger Roppe

Ryan Christopher Clark

Timothy Andrew Parr

Thomas Jonathan Seiders

David Nathan Zalatan

Yem Pham Truong

Yen Pham Truong

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Compounds as lysophosphatidic acid receptor antagonists

Polycyclic compounds as lysophosphatidic acid receptor antagonists

Described herein are compounds that are antagonists of PGDreceptors. Also described are pharmaceutical compositions and medicaments that include the antagonists of PGDreceptors described herein, as well as methods of using such antagonists of PGDreceptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD-dependent or PGD-mediated conditions or diseases.

[object Object]

Described herein are compounds that are antagonists of PGDreceptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGDreceptors. Also described herein are methods of using such antagonists of PGDreceptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD-dependent or PGD-mediated conditions or diseases.

N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors

Described herein are compounds that are antagonists of PGDreceptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGDreceptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD-dependent or PGD-mediated conditions or diseases.

Growing community of inventors

San Diego, CA, United States of America

Jill Melissa Scott